Suchergebnisse - "Cahn, Avivit"

PubPharm (26)

1

Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes : A Secondary Analysis of the DECLARE-TIMI 58 Trial

enthalten in: JAMA cardiology | 2023

von Zelniker, T. | Wiviott, S. | Mosenzon, O. | +17

2

Effects of dapagliflozin on hospitalisations in people with type 2 diabetes : post-hoc analyses of the DECLARE-TIMI 58 trial

enthalten in: The lancet. Diabetes & endocrinology | 2023

von Schechter, M. | Wiviott, S. | Raz, I. | +16

CommentIn: Lancet Diabetes Endocrinol. 2023 Apr;11(4):218-219. - PMID 36878241

3

Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose : Post Hoc Analyses From DECLARE-TIMI 58

enthalten in: Diabetes care | 2023

von Pollack, R. | Raz, I. | Wiviott, S. | +13

4

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes : Post Hoc Analyses From the DECLARE-TIMI 58 Trial

enthalten in: Diabetes care | 2022

von Mosenzon, O. | Raz, I. | Wiviott, S. | +18

5

Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes : A Prespecified Secondary Analysis of a Randomized Clinical Trial

enthalten in: JAMA cardiology | 2022

von Oyama, K. | Raz, I. | Cahn, A. | +9

6

Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial

enthalten in: European heart journal | 2022

von Oyama, K. | Raz, I. | Cahn, A. | +14

CommentIn: Eur Heart J. 2021 Oct 07;:. - PMID 34618015

7

Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure : Observations From DECLARE-TIMI 58 Trial

enthalten in: Circulation | 2022

von Furtado, R. | Raz, I. | Goodrich, E. | +17

8

Association of Baseline HbA1c With Cardiovascular and Renal Outcomes : Analyses From DECLARE-TIMI 58

enthalten in: Diabetes care | 2022

von Cahn, A. | Wiviott, S. | Mosenzon, O. | +12

CommentIn: Diabetes Care. 2022 Apr 1;45(4):766-768. - PMID 35349658

9

Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes : A Prespecified Secondary Analysis of a Randomized Clinical Trial

enthalten in: JAMA cardiology | 2021

von Zelniker, T. | Raz, I. | Mosenzon, O. | +13

10

Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort : Analyses From DECLARE-TIMI 58

enthalten in: Diabetes care | 2021

von Cahn, A. | Raz, I. | Leiter, L. | +12